A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer
NCT01519804
Completed
This multicenter, randomized, double-blind, placebo-controlled study will evaluate the efficacy and safety of onartuzumab (MetMAb) in combination with paclitaxel plus platinum in patients with incurable Stage IIIB or Stage IV squamous non-small cell lung cancer (NSCLC). Patients will be randomized to receive either onartuzumab (MetMAb) 15 mg/kg iv or placebo on Day 1 of each 21-day cycle in combination with 4 cycles of paclitaxel 200 mg/m2 iv and platinum (carboplatin/cisplatin) iv on Day 1 of e... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/01/2016
Locations: Not set, Huntsville, Alabama +68 locations
Conditions: Non-Squamous Non-Small Cell Lung Cancer
Register for Updates
Preoperative Trial of Sorafenib in Combination With Cisplatin Followed by Paclitaxel for Early Stage Breast Cancer
NCT01194869
Terminated
The purpose of this study is to identify new treatment regimens with better response rates and to find out if the combination of cisplatin and sorafenib followed by paclitaxel and sorafenib can shrink the size of your breast tumor and allow you to preserve your breast. Sorafenib is a newer drug that targets blood vessel formation and may help the chemotherapy work better. Additionally, by receiving chemotherapy before surgery, we will be able to determine if your cancer is responsive to chemothe... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2016
Locations: Grady Memorial Hospital, Atlanta, Georgia +2 locations
Conditions: Breast Cancer
Register for Updates
A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer
NCT01617668
Completed
To assess whether adding LCL161 to weekly paclitaxel enhances the efficacy of paclitaxel in women with triple negative breast cancer whose tumors are positive for a defined pattern of gene expression
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/30/2016
Locations: Highlands Oncology Group Dept of Highlands Oncology Grp, Fayetteville, Arkansas +49 locations
Conditions: Breast Cancer
Register for Updates
Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer
NCT02083679
Terminated
This is a multi-center, open-label, Phase 1b, dose escalation trial of Sym004 administered in combination with 1 of 3 platinum-doublets in subjects with Stage IV Non-Small Cell Lung Cancer (NSCLC). The sponsor decided to discontinue the development of Sym004. Also the decision was made to discontinue the development of Sym004 in NSCLC indication. The decision to discontinue Sym004 in NSCLC was not related to any safety or efficacy findings regarding Sym004. As a result of the early discontinuat... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/29/2016
Locations: Please Contact U.S. Medical Information Located in, Rockland, Massachusetts +1 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)
NCT00071188
Completed
The purpose of the run-in phase of this study is to determine the appropriate and tolerable dose of ZD6474 (200mg or 300mg) to be administered in combination with paclitaxel and carboplatin in subjects with previously untreated locally advanced or metastatic NSCLC. This phase of the trial is closed to enrollment. The purpose of the randomized phase of this study is to determine the efficacy of ZD6474 alone versus that of ZD6474 in combination with paclitaxel and carboplatin versus that of pacli... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/24/2016
Locations: Research Site, Concord, California +33 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer
NCT01488552
Completed
The Investigators in the PCRT team have developed a therapeutic regimen which attacks both the tumor compartment and the stromal compartment of pancreatic cancer and induces complete responses in a small percentage of patients with advanced stage IV pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/17/2016
Locations: TGen Clinical Research Services (TCRS), Scottsdale, Arizona +4 locations
Conditions: Stage IV Pancreatic Cancer
Register for Updates
Weekly Nanoparticle Albumin-Bound Paclitaxel (Abraxane) + Weekly Cetuximab + Radiation Therapy (IMRT, Intensity-Modulated Radiation Therapy) in Patients With Stage III-IVB Head and Neck Squamous Cell Carcinoma (HNSCC)
NCT00736619
Completed
For patients with this type of cancer, one standard treatment option is cetuximab (Erbitux®) + radiation. We wish to study the addition of albumin-bound paclitaxel (Abraxane®) to this standard regimen of cetuximab + radiation. Albumin-bound paclitaxel and cetuximab both are chemotherapy drugs which are administered by vein. Previous studies have shown that albumin-bound paclitaxel can kill head and neck cancer cells when given alone or in combination with chemotherapy. The purpose of this study... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/09/2016
Locations: Memorial Sloan Kettering Cancer Center, Basking Ridge, New Jersey +4 locations
Conditions: HEAD & NECK Cancer
Register for Updates
A Phase II Study to Evaluate Low-Dose Fractionated Radiotherapy (LDFRT)
NCT01820312
Withdrawn
The purpose of this study is to determine if low-dose radiation therapy and the chemotherapy drug paclitaxel is effective in treating head and neck cancer that has returned after treatment with standard radiation therapy alone, but cannot be removed by surgery. The overall total dose received of both the chemotherapy and radiation therapy will be less than that typically given as standard of care; however, the Food and Drug Administration (FDA) has not evaluated the safety and effectiveness of t... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2016
Locations: University of Arkansas for Medical Sciences, Little Rick, Arkansas
Conditions: Squamous Cell Carcinoma of the Head and Neck
Register for Updates
Metronomic Chemotherapy in Advanced Gastric Cancer
NCT02855788
Unknown
phase II study of weekly metronomic chemotherapy using weekly Paclitaxel, Oxaliplatin, Leucovorin and 5-FU (POLF) in patients with advanced gastric cancer
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
08/02/2016
Locations: Seattle Integrative Cancer Center, Seattle, Washington +1 locations
Conditions: Metastatic Gastric Cancer, Locally Advanced Gastric Cancer
Register for Updates
Optimized Intensity Modulated Irradiation for Head and Neck Cancer
NCT00580983
Completed
The purpose of this study is to test whether the use of advanced radiation therapy delivery techniques can spare a patient's normal tissue, including salivary glands, from radiation. This study is being done to try to reduce radiation side effects, especially mouth dryness, which happens with standard radiation methods. In order to reduce these side effects, other normal tissues may receive a different radiation dose (sometimes more) than what would have been received using standard radiation th... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2016
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: Head and Neck Cancer
Register for Updates
A Pharmacogenomics Study for Breast Cancer Patients Undergoing Adjuvant Chemotherapy With Doxorubicin (A)/Cyclophosphamide ©) and/or Weekly Paclitaxel
NCT00131963
Completed
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, cyclophosphamide, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. Giving chemotherapy after surgery may kill any tumor cells that remain after surgery. PURPOSE: This phase II trial is studying how well doxorubicin, cyclophosphamide, and/or paclitaxel work in treating wo... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/22/2016
Locations: Duke Cancer Institute, Durham, North Carolina
Conditions: Breast Cancer
Register for Updates
A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors
NCT02317419
Terminated
This is a first-in-human, open-label, multi-center, Phase 1 study of RO6927005. The study will establish the safety and tolerability profile of RO6927005 and will be conducted in two parts. In Part A, the first dose escalations will be carried out using cohorts of 1 patient. Single patient cohorts will be used to investigate increasing doses until a first dose-limiting toxicity (DLT) is reached or until grade-2 related toxicity (except infusion-related reactions), whichever comes first. At leas... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/22/2016
Locations: Not set, Bethesda, Maryland +5 locations
Conditions: Cancer
Register for Updates